Compare AWX & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AWX | CLRB |
|---|---|---|
| Founded | 1998 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3M | 11.1M |
| IPO Year | 1998 | 2008 |
| Metric | AWX | CLRB |
|---|---|---|
| Price | $2.50 | $2.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 3.9K | ★ 25.2K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $53,090,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.14 | N/A |
| 52 Week Low | $2.10 | $0.23 |
| 52 Week High | $5.43 | $10.19 |
| Indicator | AWX | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 35.74 | 51.89 |
| Support Level | $2.50 | $2.76 |
| Resistance Level | $2.66 | $3.44 |
| Average True Range (ATR) | 0.04 | 0.17 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 6.54 | 80.00 |
Avalon Holdings Corp is a waste management company. The company provides waste management services to industrial, commercial, municipal, and governmental customers in selected northeastern and midwestern U.S. markets. The company has two operating segments. The Waste management services segment which is the key revenue driver, includes waste disposal services, captive landfill operations, and saltwater injection well operations. Its Golf and related operations segment includes management of golf courses and related clubhouses, a hotel, fitness centers, tennis courts, salon and spa services, dining, banquet, and conference facilities.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.